GSK (LON:GSK) Earns Hold Rating from Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “hold” rating reissued by stock analysts at Deutsche Bank Aktiengesellschaft in a report released on Tuesday, Digital Look reports. They presently have a GBX 2,000 price target on the stock. Deutsche Bank Aktiengesellschaft’s price objective points to a potential upside of 7.50% from the company’s current price.

Several other research analysts have also commented on the stock. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a GBX 1,975 price objective on shares of GSK in a research note on Tuesday, September 8th. Berenberg Bank raised their price target on GSK from GBX 2,000 to GBX 2,200 and gave the company a “hold” rating in a research note on Tuesday, September 15th. Finally, Jefferies Financial Group restated a “buy” rating and issued a GBX 2,500 price target on shares of GSK in a report on Wednesday, July 29th. Two equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, GSK presently has a consensus rating of “Hold” and a consensus target price of GBX 2,064.38.

GSK Stock Up 0.0%

Shares of LON GSK traded up GBX 0.50 during midday trading on Tuesday, hitting GBX 1,860.50. The stock had a trading volume of 64,601,094 shares, compared to its average volume of 13,178,364. The business’s 50 day moving average is GBX 1,887.04 and its 200-day moving average is GBX 1,946.62. GSK has a 52 week low of GBX 1,520.50 and a 52 week high of GBX 2,282. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 103.36. The company has a market cap of £74.55 billion, a P/E ratio of 15.79, a PEG ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK) last released its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. As a group, analysts predict that GSK will post 175.980975 EPS for the current year.

Insider Buying and Selling

In other GSK news, insider Anne Beal acquired 637 shares of the stock in a transaction dated Friday, September 18th. The stock was acquired at an average price of GBX 4,985 per share, with a total value of £31,754.45. Also, insider Jonathan Symonds bought 1,500 shares of the business’s stock in a transaction that occurred on Friday, September 18th. The shares were acquired at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Insiders bought 2,144 shares of company stock valued at $6,009,566 over the last 90 days. Company insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.